• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Multicenter international assessment of a SARS-CoV-2 RT-LAMP test for point of care clinical application

tetano

Editor, Senior Moderator
PLoS One


. 2022 May 11;17(5):e0268340.
doi: 10.1371/journal.pone.0268340. eCollection 2022.
Multicenter international assessment of a SARS-CoV-2 RT-LAMP test for point of care clinical application


Suying Lu[SUP] 1 2 3 [/SUP], David Duplat[SUP] 4 [/SUP], Paula Benitez-Bolivar[SUP] 4 [/SUP], Cielo León[SUP] 4 [/SUP], Stephany D Villota[SUP] 5 [/SUP], Eliana Veloz-Villavicencio[SUP] 5 [/SUP], Valentina Arévalo[SUP] 5 [/SUP], Katariina Jaenes[SUP] 6 [/SUP], Yuxiu Guo[SUP] 7 [/SUP], Seray Cicek[SUP] 7 [/SUP], Lucas Robinson[SUP] 8 [/SUP], Philippos Peidis[SUP] 1 2 3 [/SUP], Joel D Pearson[SUP] 1 2 3 [/SUP], Jim Woodgett[SUP] 1 9 [/SUP], Tony Mazzulli[SUP] 2 10 [/SUP], Patricio Ponce[SUP] 5 [/SUP], Silvia Restrepo[SUP] 11 [/SUP], John M González[SUP] 12 [/SUP], Adriana Bernal[SUP] 13 [/SUP], Marcela Guevara-Suarez[SUP] 14 [/SUP], Keith Pardee[SUP] 6 7 15 [/SUP], Varsovia E Cevallos[SUP] 5 [/SUP], Camila González[SUP] 4 [/SUP], Rod Bremner[SUP] 1 2 3 [/SUP]



Affiliations

Abstract

Continued waves, new variants, and limited vaccine deployment mean that SARS-CoV-2 tests remain vital to constrain the coronavirus disease 2019 (COVID-19) pandemic. Affordable, point-of-care (PoC) tests allow rapid screening in non-medical settings. Reverse-transcription loop-mediated isothermal amplification (RT-LAMP) is an appealing approach. A crucial step is to optimize testing in low/medium resource settings. Here, we optimized RT-LAMP for SARS-CoV-2 and human β-actin, and tested clinical samples in multiple countries. "TTTT" linker primers did not improve performance, and while guanidine hydrochloride, betaine and/or Igepal-CA-630 enhanced detection of synthetic RNA, only the latter two improved direct assays on nasopharygeal samples. With extracted clinical RNA, a 20 min RT-LAMP assay was essentially as sensitive as RT-PCR. With raw Canadian nasopharygeal samples, sensitivity was 100% (95% CI: 67.6% - 100%) for those with RT-qPCR Ct values ≤ 25, and 80% (95% CI: 58.4% - 91.9%) for those with 25 < Ct ≤ 27.2. Highly infectious, high titer cases were also detected in Colombian and Ecuadorian labs. We further demonstrate the utility of replacing thermocyclers with a portable PoC device (FluoroPLUM). These combined PoC molecular and hardware tools may help to limit community transmission of SARS-CoV-2.
 
Back
Top Bottom